PapGene Aims to Commercialize Bladder Cancer Surveillance Test With NIH Contract Funds
Baltimore, Maryland-based biotechnology company PapGene has secured a potential $2.2 million contract from a National Institutes of Health center to study and commercialize a recurrent bladder cancer surveillance test. PapGene said Tuesday it will receive $299,824 funds from NIH’s National Cancer Institute under the first phase of the Fast-Track Small Business Innovation Research contract to demonstrate the accuracy and clinical validity of […] More